HAVCR2 and hematologic disorder: TIM-3 has been identified as an immune checkpoint target for both solid tumors and hematologic malignancies.26 A blockade of TIM-3 has been shown to improve the proliferation and activity of tumor antigen-specific T cells.27 The use of anti-TIM-3 antibodies, either alone or in combination with other drugs in clinical trials, has been found to be effective in treating a variety of cancers.